Announcement of The Consolidated Financial Report for The 3rd Quarter of 2025
2025.11.6
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/11/06 | Time of announcement | 15:26:52 |
| Subject | Announcement of The Consolidated Financial Report for The 3rd Quarter of 2025 | ||||
| Date of events | 2025/11/06 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2025/11/06 2.Date of the audit committee approved:2025/11/06 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2025/01/01~2025/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):4,790,870 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,785,701 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,346,477 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,678,857 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):1,329,752 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):1,255,910 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):5.05 11.Total assets end of the period (thousand NTD):11,544,826 12.Total liabilities end of the period (thousand NTD):3,881,780 13.Equity attributable to owners of parent end of the period (thousand NTD):6,861,721 14.Any other matters that need to be specified:None. |
||||